References
- Livermore DM, Andrews JM, Hawkey PM, Ho PL, Keness Y, Doi Y, et al. Are susceptibility tests enough, or should laboratories still seek ESBLs and carbapenemases directly? J Antimicrob Chemother. 2012;67:1569–77.10.1093/jac/dks088
- Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase producing bacteria. Lancet Infect Dis. 2009;9(4):228–36.10.1016/S1473-3099(09)70054-4
- Clinical Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Twentieth Informational Supplement. Document M100–S20. Wayne, PA: CLSI; 2010.
- Clinical Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Twentieth Informational Supplement. Document M100–S24. Wayne, PA: CLSI; 2014.
- Nguyen HM, Shier KL, Graber CJ. Determining a clinical framework for use of cefepime and β-lactam/β-lactamase inhibitors in the treatment of infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother. 2014;69:871–80.10.1093/jac/dkt450
- Vardakas KZ, Tansarli GS, Rafailidis PI, Falagas ME. Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamases: a systematic review and meta-analysis. J Antimicrob Chemother. 2012;67(12):2793–803.10.1093/jac/dks301
- Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Document M7-A9, Vol. 29, No. 2; Wayne, PA: CLSI; 2012.
- Clinical Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Twentieth Informational Supplement. Document M100-S23. Wayne, PA: CLSI; 2013.
- European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 2.0. EUCAST; 2014. Available from http://www.eucast.org/clinical_breakpoints/.
- Monstein HJ, Östholm-Balkhed Å., Nilsson MV, Nilsson M, Dornbusch K, Nilsson LE. Multiplex PCR amplification assay for the detection of blaSHV, blaTEM and blaCTX-M genes in Enterobacteriaceae. APMIS. 2007;115:1400–8.10.1111/apm.2007.115.issue-12
- Lee NY, Lee CC, Huang WH, Tsui KC, Hsueh PR, Ko WC. Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended spectrum β-Lactamase Producing Enterobacteriaceae: MIC matters. Clin Infect Dis. 2013;56(4):488–95.10.1093/cid/cis916
- Endimiani A, Perez F, Bonomo RA. Cefepime: a reappraisal in an era of increasing antimicrobial resistance. Expert Rev Anti Infect Ther. 2008;6(6):805–824.10.1586/14787210.6.6.805
- Paterson DL, Ko WC, Von Gottberg AV, Casellas JM, Mulazimoglu L, Klugman KP, et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum β-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol. 2001;39(6):2206–12.10.1128/JCM.39.6.2206-2212.2001
- Bhat SV, Peleg AY, Lodise TP Jr, Shutt KA, Capitano B, Potoski BA, et al. Failure of current cefepime breakpoints to predict clinical outcomes of bacteremia caused by Gram-negative organisms. Antimicrob Agents Chemother. 2007;51(12):4390–5.10.1128/AAC.01487-06
- Bonnet R. Growing group of extended-spectrum β-lactamases: the CTX-M enzymes. Antimicrob Agents Chemother. 2004;48:1–14.10.1128/AAC.48.1.1-14.2004